While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said. The Food and Drug Administration (FDA) approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback